Loading
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (3 ops.)
Latest filing published 06 Jan 2014 for Aveo Pharmaceuticals, INC., €4,130.
Insider track record
Disclosed buys
5
Disclosed sells
3
Signal history
No signal scores available.
Closed purchases
Market purchases
5
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Robert C. Young: trading record in brief
Robert C. Young discloses dealings in 3 companies, chiefly Human Genome Sciences Inc, West Pharmaceutical Services Inc and Aveo Pharmaceuticals, Inc. We count 52 filings; the first trade dates from 5 January 2006 and the latest from 2 January 2014.
Both buying and selling appear: 5 purchases worth €30k, against 3 sales worth €128k. On balance, insiders were net sellers of €97k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 26 share grants and 11 option exercises.
A typical purchase (the median) is worth €6,165.
On 6 January 2014 came the latest disclosure, a share grant for €4,130 in Aveo Pharmaceuticals, Inc. The most recent open-market purchase was published on 20 February 2013, 4,993 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Robert C. Young
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations50 total
3,159 shares@ US$1.80Common StockSEC:0001181431-14-001297:0
2,734 shares@ US$2.08Common StockSEC:0001181431-13-052340:0
2,221 shares@ US$2.56Common StockSEC:0001181431-13-037952:0
844 shares@ US$7.25Common StockSEC:0001181431-13-023328:0
990 shares@ US$6.60Common StockSEC:0001181431-13-010921:0
Canonical exit: 20 May 2013 (T+90)
2,200 shares@ US$6.78Common StockSEC:0001181431-12-064663:0
Canonical exit: 13 Mar 2013 (T+90)
171 shares@ US$6.78Common StockSEC:0001181431-12-064663:1
Canonical exit: 13 Mar 2013 (T+90)
1,250 shares@ US$6.41Common StockSEC:0001181431-12-062271:0
Canonical exit: 3 Mar 2013 (T+90)
1,000 shares@ US$8.63Common StockSEC:0001181431-12-044681:0
Canonical exit: 6 Nov 2012 (T+90)
13,834 shares@ US$14.25Common StockSEC:0001225208-12-016976:1
18,851.94 shares@ US$14.25Common StockSEC:0001225208-12-016976:2
2,500 shares0Common StockSEC:0001225208-12-012859:0
3,468 shares@ US$19.37Common StockSEC:0001225208-11-020936:0
1,114 shares@ US$40.03Common StockSEC:0001225208-11-020936:1
2,354 shares@ US$40.03Common StockSEC:0001225208-11-020936:2
2,354 shares@ US$40.03Common StockSEC:0001225208-11-020944:0
4,361 shares@ US$7.44Common StockSEC:0001181431-11-046483:0
4,361 shares@ US$15.76Common StockSEC:0001181431-11-046483:1
2,139 shares@ US$7.44Common StockSEC:0001181431-11-046483:2
2,500 shares0Common StockSEC:0001225208-11-014340:0
2,325 shares0Common StockSEC:0001225208-11-013249:0
2,830 shares@ US$2.09Common StockSEC:0001225208-10-017544:0
1,000 shares0Common StockSEC:0001225208-10-012888:0
1,000 shares0Common StockSEC:0001225208-10-012888:1
2,617 shares0Common StockSEC:0001225208-10-012024:0
25 of 50 declarations
